title: Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.
abstract: The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects during 3-h paired euglycemic clamp studies using one of three doses (rhIGF-I 0.2, 0.4, and 0.8 micrograms/kg.min and insulin 0.2, 0.4, and 0.8 mU/kg.min, doses chosen to produce equivalent increases in glucose uptake). In younger subjects, rhIGF-I infusions suppressed insulin by 19-33%, C-peptide by 47-59% and glucagon by 33-47% (all, P < 0.02). The suppression of C-peptide was less pronounced with insulin than with rhIGF-I (P < 0.007). The metabolic responses to rhIGF-I and insulin were remarkably similar: not only did both hormones increase glucose uptake and oxidation in a nearly identical fashion, but they also produced similar suppression of glucose production, free fatty acid levels, and fat oxidation rates. In contrast, rhIGF-I had a more pronounced amino acid-lowering effect than did insulin (P < 0.004). In middle-aged subjects, basal IGF-I levels were 44% lower (P < 0.0001) whereas basal insulin and C-peptide were 20-25% higher than in younger subjects. Age did not alter the response to rhIGF-I. However, insulin-induced stimulation of glucose uptake was blunted in older subjects (P = 0.05). Our data suggest that absolute IGF-I and relative insulin deficiency contribute to adverse metabolic changes seen in middle age.
authors.affiliation: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut 06510.
authors.forename: S D
authors.initials: SD
authors.lastname: Boulware
authors.forename: W V
authors.initials: WV
authors.lastname: Tamborlane
authors.forename: N J
authors.initials: NJ
authors.lastname: Rennert
authors.forename: N
authors.initials: N
authors.lastname: Gesundheit
authors.forename: R S
authors.initials: RS
authors.lastname: Sherwin
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D002096:C-Peptide / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D002096:C-Peptide; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D005934:Glucagon; D005947:Glucose